TRACON Pharmaceuticals Company Profile (NASDAQ:TCON)

About TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON Pharmaceuticals logoTRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TCON
  • CUSIP: N/A
  • Web:
  • Market Cap: $50.8 million
  • Outstanding Shares: 16,655,000
Average Prices:
  • 50 Day Moving Avg: $3.41
  • 200 Day Moving Avg: $3.41
  • 52 Week Range: $2.80 - $7.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.67
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.69 million
  • Price / Sales: 18.88
  • Book Value: $1.04 per share
  • Price / Book: 2.93
  • EBITDA: ($24,840,000.00)
  • Net Margins: -963.11%
  • Return on Equity: -119.93%
  • Return on Assets: -67.64%
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 3.57%
  • Quick Ratio: 3.57%
  • Average Volume: 129,014 shs.
  • Beta: 2.52
  • Short Ratio: 6.22

Frequently Asked Questions for TRACON Pharmaceuticals (NASDAQ:TCON)

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.52) by $0.12. The business had revenue of $0.63 million for the quarter, compared to analysts' expectations of $0.81 million. TRACON Pharmaceuticals had a negative return on equity of 119.93% and a negative net margin of 963.11%. View TRACON Pharmaceuticals' Earnings History.

When will TRACON Pharmaceuticals make its next earnings announcement?

TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for TRACON Pharmaceuticals.

Where is TRACON Pharmaceuticals' stock going? Where will TRACON Pharmaceuticals' stock price be in 2017?

3 analysts have issued 1-year target prices for TRACON Pharmaceuticals' stock. Their predictions range from $6.00 to $10.00. On average, they expect TRACON Pharmaceuticals' share price to reach $8.00 in the next twelve months. View Analyst Ratings for TRACON Pharmaceuticals.

Who are some of TRACON Pharmaceuticals' key competitors?

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the folowing people:

  • Charles P. Theuer, President, Chief Executive Officer, Director
  • Patricia L. Bitar CPA, Chief Financial Officer
  • H Casey Logan, Chief Business Officer
  • William R. LaRue, Independent Director
  • Martin A. Mattingly Ph.D., Independent Director
  • J. Rainer Twiford Ph.D., J.D., Independent Director
  • Paul Walker, Independent Director
  • Stephen T. Worland Ph.D., Independent Director

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

How do I buy TRACON Pharmaceuticals stock?

Shares of TRACON Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TRACON Pharmaceuticals' stock price today?

One share of TRACON Pharmaceuticals stock can currently be purchased for approximately $3.05.

MarketBeat Community Rating for TRACON Pharmaceuticals (NASDAQ TCON)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  98 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  166
MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for TRACON Pharmaceuticals (NASDAQ:TCON) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $8.00 (162.30% upside)
Consensus Price Target History for TRACON Pharmaceuticals (NASDAQ:TCON)
Price Target History for TRACON Pharmaceuticals (NASDAQ:TCON)
Analysts' Ratings History for TRACON Pharmaceuticals (NASDAQ:TCON)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/13/2017Stifel NicolausLower Price TargetBuy -> Buy$14.00 -> $6.00HighView Rating Details
1/3/2017Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
12/21/2016Jefferies Group LLCInitiated CoverageBuy$10.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$15.00N/AView Rating Details
2/1/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperformN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for TRACON Pharmaceuticals (NASDAQ:TCON)
Earnings by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)
Earnings History by Quarter for TRACON Pharmaceuticals (NASDAQ TCON)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.25)N/AView Earnings Details
8/8/2017Q2 2017($0.52)($0.40)$0.81 million$0.63 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.47)($0.44)$0.92 million$0.63 millionViewN/AView Earnings Details
8/10/2016Q2($0.62)($0.68)$1.27 million$0.81 millionViewListenView Earnings Details
5/11/2016Q1($0.70)($0.54)$1.21 millionViewListenView Earnings Details
2/18/2016Q4($0.62)($0.91)$1.40 millionViewListenView Earnings Details
11/3/2015Q3($0.51)($0.53)$1.06 million$1.18 millionViewListenView Earnings Details
8/5/2015Q215($0.42)($0.24)$1.02 million$4.20 millionViewListenView Earnings Details
5/13/2015Q1($0.37)($0.50)$1.13 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for TRACON Pharmaceuticals (NASDAQ:TCON)
2017 EPS Consensus Estimate: ($1.50)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.45)($0.45)($0.45)
Q2 20171($0.51)($0.51)($0.51)
Q3 20171($0.10)($0.10)($0.10)
Q4 20171($0.44)($0.44)($0.44)
(Data provided by Zacks Investment Research)


Dividend History for TRACON Pharmaceuticals (NASDAQ:TCON)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for TRACON Pharmaceuticals (NASDAQ:TCON)
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 31.65%
Insider Trades by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)
Institutional Ownership by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)
Insider Trades by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/2/2017William R LarueDirectorSell2,500$2.69$6,725.00View SEC Filing  
11/29/2016Peter W SonsiniMajor ShareholderBuy869,565$5.75$4,999,998.75View SEC Filing  
6/3/2016Ronald L ShazerInsiderSell1,003$7.48$7,502.44View SEC Filing  
10/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell1,500$9.90$14,850.00View SEC Filing  
10/15/2015Jafco Super V3 Investment LimiMajor ShareholderSell5,300$10.16$53,848.00View SEC Filing  
10/13/2015Jafco Super V3 Investment Limimajor shareholderSell3,168$10.01$31,711.68View SEC Filing  
10/9/2015Jafco Super V3 Investment Limimajor shareholderSell1,448$10.01$14,494.48View SEC Filing  
10/8/2015Jafco Super V3 Investment Limimajor shareholderSell21,920$10.10$221,392.00View SEC Filing  
10/5/2015Jafco Super V3 Investment Limimajor shareholderSell15,100$10.08$152,208.00View SEC Filing  
9/25/2015Jafco Super V3 Investment LimiMajor ShareholderSell7,600$12.13$92,188.00View SEC Filing  
9/24/2015Jafco Super V3 Investment Limimajor shareholderSell22,303$12.99$289,715.97View SEC Filing  
9/22/2015Jafco Super V3 Investment Limimajor shareholderSell39,426$14.02$552,752.52View SEC Filing  
9/21/2015Jafco Super V3 Investment Limimajor shareholderSell18,200$14.48$263,536.00View SEC Filing  
9/18/2015Charles TheuerCEOSell10,000$17.34$173,400.00View SEC Filing  
9/18/2015H Casey LoganinsiderSell5,000$17.34$86,700.00View SEC Filing  
9/17/2015Jafco Super V3 Investment Limimajor shareholderSell42,344$11.78$498,812.32View SEC Filing  
9/14/2015Jafco Super V3 Investment Limimajor shareholderSell60,038$11.78$707,247.64View SEC Filing  
9/10/2015Charles TheuerCEOSell3,516$12.00$42,192.00View SEC Filing  
9/9/2015Jafco Super V3 Investment Limimajor shareholderSell12,000$10.71$128,520.00View SEC Filing  
9/8/2015Jafco Super V3 Investment Limimajor shareholderSell5,700$10.47$59,679.00View SEC Filing  
9/4/2015Jafco Super V3 Investment Limimajor shareholderSell6,600$10.48$69,168.00View SEC Filing  
9/3/2015Jafco Super V3 Investment Limimajor shareholderSell15,300$10.51$160,803.00View SEC Filing  
9/1/2015Jafco Super V3 Investment Limimajor shareholderSell14,000$10.42$145,880.00View SEC Filing  
8/24/2015Jafco Super V3 Investment LimiMajor ShareholderSell3,000$11.00$33,000.00View SEC Filing  
8/20/2015Jafco Super V3 Investment Limimajor shareholderSell10,683$11.36$121,358.88View SEC Filing  
8/18/2015Jafco Super V3 Investment LimiMajor ShareholderSell11,174$11.71$130,847.54View SEC Filing  
8/13/2015Jafco Super V3 Investment LimiMajor ShareholderSell9,361$11.60$108,587.60View SEC Filing  
2/4/2015M James BarrettMajor ShareholderBuy500,000$10.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for TRACON Pharmaceuticals (NASDAQ:TCON)
Latest Headlines for TRACON Pharmaceuticals (NASDAQ:TCON)
DateHeadline logoTRACON Pharmaceuticals Announces Multiple TRC105 Poster ... - GlobeNewswire (press release) - October 17 at 7:54 AM logoTRACON Pharmaceuticals Announces Multiple TRC105 Poster Presentations at 18th IASLC World Conference on Lung Cancer - October 16 at 7:01 AM logoTRACON Pharmaceuticals, Inc. (TCON) Rating Lowered to Hold at Zacks Investment Research - October 11 at 1:32 PM logoETFs with exposure to TRACON Pharmaceuticals, Inc. : October 6, 2017 - October 7 at 9:04 AM logoTRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 - October 6 at 11:05 AM logo Brokerages Expect TRACON Pharmaceuticals, Inc. (TCON) Will Announce Quarterly Sales of $7.60 Million - October 3 at 9:28 AM logo$7.60 Million in Sales Expected for TRACON Pharmaceuticals, Inc. (TCON) This Quarter - September 14 at 8:48 AM logoChristmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High - September 8 at 9:07 AM logoTRACON Pharmaceuticals Announces Completion of Enrollment in Randomized Phase 2b TRAXAR Study of TRC105 and Inlyta® in Renal Cell Carcinoma - September 7 at 9:49 AM logoTRACON Pharmaceuticals, Inc. (TCON) Expected to Announce Quarterly Sales of $7.60 Million - August 27 at 10:52 AM logoTRACON Pharmaceuticals Announces Positive Results from National Cancer Institute Phase 1/2 Trial of TRC105 and Nexavar® in Hepatocellular Cancer Published in Clinical Cancer Research - August 16 at 8:03 AM logoQ3 2017 EPS Estimates for TRACON Pharmaceuticals Inc (NASDAQ:TCON) Increased by Analyst - August 14 at 1:24 AM logoFY2019 EPS Estimates for TRACON Pharmaceuticals, Inc. (TCON) Increased by Analyst - August 11 at 4:28 PM logoTRACON Pharmaceuticals, Inc. (TCON) Announces Earnings Results, Beats Expectations By $0.12 EPS - August 10 at 3:16 PM logoEdited Transcript of TCON earnings conference call or presentation 8-Aug-17 8:30pm GMT - August 10 at 8:36 AM logoTRACON Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update - August 9 at 8:05 AM logoTracon reports 2Q loss - August 9 at 8:05 AM logoTRACON Pharmaceuticals, Inc. (TCON) Expected to Post Quarterly Sales of $810,000.00 - August 8 at 7:34 AM logoTRACON Pharmaceuticals, Inc. (TCON) Expected to Announce Earnings of -$0.53 Per Share - August 6 at 6:08 PM logoReviewing TRACON Pharmaceuticals (NASDAQ:TCON) & China Biologic Products (CBPO) - August 4 at 6:28 PM logoTRACON to Report Second Quarter Company Highlights and Financial Results on August 8, 2017 - August 2 at 7:42 AM logoTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Set to Announce Earnings on Tuesday - August 1 at 7:30 AM logoTRACON Pharmaceutical (TCON) & Santen Commence Phase 2a Study of DE-122 - July 28 at 8:37 AM logoSanten and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration - July 26 at 8:40 AM logo$810,000.00 in Sales Expected for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) This Quarter - July 19 at 1:54 PM logo Analysts Anticipate TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to Announce -$0.53 EPS - July 17 at 2:28 PM logoTRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer - May 24 at 8:56 AM logoTRACON Pharmaceuticals Announces TRC694 Data Presentation at Upcoming AACR Annual Meeting - March 27 at 7:23 PM logoTracon Pharmaceuticals Inc. (TCON) Is Rising On Aspire Capital Fund Agreement - March 14 at 7:40 PM logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ - March 14 at 7:40 PM logoTRACON Pharmaceuticals to Present at the 29th Annual Roth Conference - GlobeNewswire (press release) - March 6 at 7:23 PM logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements - March 1 at 9:35 AM logoTRACON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report - March 1 at 9:35 AM logoTRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update - February 28 at 7:47 PM logoQ4 2016 TRACON Pharmaceuticals Inc Earnings Release - After Market Close - February 28 at 11:37 AM logoTracon Tanks on Brain Cancer Drug Failure (TCON) - Investopedia - February 13 at 8:39 PM logoTracon Pharma Tanks on Brain Cancer Drug Failure - February 13 at 3:38 PM logoHealth Care Sector Update for 02/10/2017: TCON,IMMU,SGEN,BSTG - Nasdaq - February 12 at 1:18 AM logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - February 11 at 8:17 PM logoMid-Morning Market Update: Markets Open Higher; NVIDIA Beats Q4 Views - February 11 at 5:05 AM logoTRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma - February 10 at 5:57 AM logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin - February 9 at 6:04 AM logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers - February 9 at 6:04 AM logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos - January 10 at 1:19 AM logoTracon Pharmaceuticals: ~$5 Biotech Stock With Plenty Of Catalysts In 2017 - January 7 at 3:51 AM logo8:05 am Tracon Pharmaceuticals receives special protocol assessment agreement from FDA for phase 3 clinical trial of TRC105 in Angiosarcoma - January 3 at 9:21 AM logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and - December 22 at 3:58 AM logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and - December 14 at 5:46 AM



TRACON Pharmaceuticals (TCON) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.